[(1S)-1-[(2S)-5-hydroxy-5-pentyloxolan-2-yl]ethyl]carbamic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧唑烯
• 英文名称: [(1S)-1-[(2S)-5-hydroxy-5-pentyloxolan-2-yl]ethyl]carbamic acid
• 化学式: C₁₂H₂₃NO₄
• 分子量: 245.32
• InChiKey: MYEQJFQELODXDG-HVFQMFNGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  78.8
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Novel Bicyclic Pyridinones
  申请人：Pfizer Inc.

  公开号：US20140088111A1

  公开（公告）日：2014-03-27

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  所述化合物及其药用可接受盐已被披露，其中所述化合物具有规范中定义的Formula I结构。相应的药用组合物、治疗方法、合成方法和中间体也已被披露。
• Novel Pyrido[1,2-a]Pryazines And Their Use In The Treatment of Neurodegenerative and Neurological Disorders
  申请人：Pfizer Inc.

  公开号：US20150072990A1

  公开（公告）日：2015-03-12

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明揭示了化合物及其药学上可接受的盐，其中化合物的结构如规格中定义的公式I。同时还揭示了相应的药物组合物、治疗方法、合成方法和中间体。
• SUBSTITUTED ALKYL DIARYL DERIVATIVES, METHODS OF PREPARATION AND USES
  申请人：TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  公开号：US20150266819A1

  公开（公告）日：2015-09-24

  Compounds according to Formula I are provided: and salts thereof, wherein Q 1 , Q 2 , R 3 , R 4 , X, and Y are as defined herein. Methods for preparing compounds of Formula I are also provided, as well as methods of treating cellular proliferative disorders, such as cancer, using compounds of Formula (I). Q 2 -X—Y—CHR 3 —CHR 4 -Q 1 (I)

  提供符合公式I的化合物和其盐，其中Q1、Q2、R3、R4、X和Y的定义如本文所述。还提供了制备公式I化合物的方法，以及使用公式（I）化合物治疗细胞增殖性疾病（如癌症）的方法。Q2-X—Y—CHR3—CHR4-Q1（I）
• Novel Pyrido[1,2-a]Pryazines And Their Use in the Treatment of Neurodegenerative and Neurological Disorders
  申请人：Pfizer Inc.

  公开号：US20160024088A1

  公开（公告）日：2016-01-28

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本文披露了化合物及其药学上可接受的盐，其中该化合物的结构如规范中定义的I式。同时还披露了相应的药物组合物、治疗方法、合成方法和中间体。
• Substituted alkyl diaryl derivatives, methods of preparation and uses
  申请人：TEMPLE UNIVERSITY—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

  公开号：US10207989B2

  公开（公告）日：2019-02-19

  Compounds according to Formula I are provided: and salts thereof, wherein Q1, Q2, R3, R4, X, and Y are as defined herein. Methods for preparing compounds of Formula I are also provided, as well as methods of treating cellular proliferative disorders, such as cancer, using compounds of Formula (I). Q2-X—Y—CHR3—CHR4-Q1  (I)

  提供了根据式 I 的化合物：及其盐类，其中 Q1、Q2、R3、R4、X 和 Y 如本文所定义。还提供了制备式 I 化合物的方法，以及使用式 (I) 化合物治疗细胞增殖性疾病（如癌症）的方法。 Q2-X-Y-CHR3-CHR4-Q1 (I)